These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 8973053)

  • 1. Bioavailability and pharmacokinetic disposition of tacrine in elderly patients with Alzheimer's disease.
    Lou G; Montgomery PR; Sitar DS
    J Psychiatry Neurosci; 1996 Nov; 21(5):334-9. PubMed ID: 8973053
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tacrine in Alzheimer's disease: pharmacokinetic and clinical comparison of oral and rectal administration.
    Ahlin A; Hassan M; Junthé T; Nybäck H
    Int Clin Psychopharmacol; 1994; 9(4):263-70. PubMed ID: 7868848
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Steady-state pharmacokinetics of tacrine in patients with Alzheimer's disease.
    Cutler NR; Sedman AJ; Prior P; Underwood BA; Selen A; Balogh L; Kinkel AW; Gracon SI; Gamzu ER
    Psychopharmacol Bull; 1990; 26(2):231-4. PubMed ID: 2236461
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of tetrahydroaminoacridine: relations to clinical and biochemical effects in Alzheimer patients.
    Ahlin A; Adem A; Junthé T; Ohman G; Nybäck H
    Int Clin Psychopharmacol; 1992; 7(1):29-36. PubMed ID: 1624754
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma tacrine concentrations are significantly increased by concomitant hormone replacement therapy.
    Laine K; Palovaara S; Tapanainen P; Manninen P
    Clin Pharmacol Ther; 1999 Dec; 66(6):602-8. PubMed ID: 10613616
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nose-to-brain delivery of tacrine.
    Jogani VV; Shah PJ; Mishra P; Mishra AK; Misra AR
    J Pharm Pharmacol; 2007 Sep; 59(9):1199-205. PubMed ID: 17883890
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The pharmacological effects of ginkgo biloba, a plant extract, on the brain of dementia patients in comparison with tacrine.
    Itil TM; Eralp E; Ahmed I; Kunitz A; Itil KZ
    Psychopharmacol Bull; 1998; 34(3):391-7. PubMed ID: 9803773
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of idebenone versus tacrine in patients with Alzheimer's disease: results of a randomized, double-blind, parallel-group multicenter study.
    Gutzmann H; Kühl KP; Hadler D; Rapp MA
    Pharmacopsychiatry; 2002 Jan; 35(1):12-8. PubMed ID: 11819153
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of the value of therapeutic monitoring of tacrine in Alzheimer's disease.
    Roberts CJ; Ford JM; Truman CA; Scott M; Mäkelä PM; Wilcock GK
    Eur J Clin Pharmacol; 1998; 54(9-10):721-4. PubMed ID: 9923574
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Balance sheet of tolerance-efficacy on the use of tacrine in 100 cases of Alzheimer's disease].
    Estadieu MC; Machou C; Berthezène P; Pastor MJ; Angelini B; Bohor M; Bongrand MC; Timon-David P; Gastaut JL; Allain H; Michel BF
    Therapie; 1998; 53(1):67-76. PubMed ID: 9773102
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A review of the randomized controlled trials of tacrine in the treatment of Alzheimer's disease: methodologic considerations.
    Conway EL
    Clin Neuropharmacol; 1998; 21(1):8-17. PubMed ID: 9579280
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical pharmacokinetics of drugs for Alzheimer's disease.
    Parnetti L
    Clin Pharmacokinet; 1995 Aug; 29(2):110-29. PubMed ID: 7586900
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tacrine: a second look. An outdated drug to be discarded.
    Prescrire Int; 1999 Feb; 8(39):16-8. PubMed ID: 10557569
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Convulsive crisis as a possible adverse reaction to the treatment with tacrine in Alzheimer's disease].
    García-Díaz JD; Fraguas C; Garcimartín C
    Med Clin (Barc); 1998 Sep; 111(7):279. PubMed ID: 9789247
    [No Abstract]   [Full Text] [Related]  

  • 15. [Tacrine].
    Dávila C; Viteri C; de Castro P
    Rev Med Univ Navarra; 1997; 41(1):58-64. PubMed ID: 9527715
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of tacrine hydrochloride in Alzheimer's disease.
    Forsyth DR; Wilcock GK; Morgan RA; Truman CA; Ford JM; Roberts CJ
    Clin Pharmacol Ther; 1989 Dec; 46(6):634-41. PubMed ID: 2598567
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of tacrine oral clearance by cimetidine.
    Forgue ST; Reece PA; Sedman AJ; deVries TM
    Clin Pharmacol Ther; 1996 Apr; 59(4):444-9. PubMed ID: 8612390
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical pharmacokinetics of tacrine.
    Madden S; Spaldin V; Park BK
    Clin Pharmacokinet; 1995 Jun; 28(6):449-57. PubMed ID: 7656503
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical characterization of intestinal absorption and metabolism of promising anti-Alzheimer's dimer bis(7)-tacrine.
    Zhang L; Yu H; Li WM; Cheung MC; Pang YP; Gu ZM; Chan K; Wang YT; Zuo Z; Han YF
    Int J Pharm; 2008 Jun; 357(1-2):85-94. PubMed ID: 18358649
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New performance of biosensor technology for Alzheimer's disease drugs: in vitro comparison of tacrine and 7-methoxytacrine.
    Pohanka M; Kuca K; Kassa J
    Neuro Endocrinol Lett; 2008 Oct; 29(5):755-8. PubMed ID: 18987590
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.